Julie Mabry
Family · Greenville, MSNPI 1326650110
Payments from drug & device makers
Across 174 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$584
- Bayer$398
- Fresenius USA Marketing, Inc.$376
- Mallinckrodt Hospital Products Inc.$368
- Amgen$345
- Aurinia Pharma U.S., Inc.$303
- plus $951 from 11 others
What the payments were for
- Food & beverage$3,325100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $584 |
| Bayer | 25 | $398 |
| Fresenius USA Marketing, Inc. | 18 | $376 |
| Mallinckrodt Hospital Products Inc. | 19 | $368 |
| Amgen | 17 | $345 |
| Aurinia Pharma U.S., Inc. | 15 | $303 |
| Akebia Therapeutics Inc | 10 | $182 |
| Ardelyx, Inc. | 7 | $161 |
| ANI Pharmaceuticals, Inc. | 8 | $149 |
| Boehringer Ingelheim | 7 | $117 |
| Novo Nordisk | 6 | $115 |
| GSK | 4 | $90 |
| Calliditas Therapeutics US Inc. | 2 | $42 |
| Novartis | 2 | $36 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $18 |
How this compares
$3,325 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 67 | $209,241 |
| AuryxiaFerric Citrate | 55 | $186,637 |
| FarxigaDapagliflozin Propanediol | 199 | $167,564 |
| LokelmaSodium Zirconium Cyclosilicate | 56 | $32,355 |
| KerendiaFinerenone | 30 | $27,177 |
| EliquisApixaban | 25 | $23,430 |
| Sevelamer Carbonate | 122 | $22,612 |
| EntrestoSacubitril/Valsartan | 23 | $21,308 |
| MounjaroTirzepatide | 15 | $20,352 |
| JardianceEmpagliflozin | 26 | $16,942 |
| JanuviaSitagliptin Phosphate | 21 | $15,532 |
| LinzessLinaclotide | 13 | $10,600 |
| Lanthanum Carbonate | 21 | $9,523 |
| DapagliflozinDapagliflozin Propanediol | 16 | $8,073 |
| Calcium Acetate | 12 | $2,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $376 | $209,24167 claims |
| AstraZenecaFarxiga, Lokelma | $584 | $199,919255 claims |
| Akebia Therapeutics IncAuryxia | $182 | $186,63755 claims |
| BayerKerendia | $398 | $27,17730 claims |
| NovartisEntresto | $36 | $21,30823 claims |
| Lilly USA, LLCMounjaro | $19 | $20,35215 claims |
| Boehringer IngelheimJardiance | $117 | $16,94226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Greenville
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.